Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Xenon ( (XENE) ) has issued an update.
Xenon Pharmaceuticals announced significant progress in their pipeline programs, highlighting key milestones anticipated for 2025. Notably, they expect the first Phase 3 topline data for azetukalner in focal onset seizures in the second half of 2025, marking a potential transition from a clinical to commercial stage. The company is also expanding its research into major depressive disorder with new Phase 3 trials and plans to file multiple INDs for early-stage candidates, underscoring its commitment to broadening indications and advancing its neuroscience portfolio.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development, and delivery of life-changing therapeutics for patients with neurological conditions. Their market focus includes developing treatments for epilepsy and other neuropsychiatric disorders, with a strong emphasis on advancing their ion channel portfolio.
YTD Price Performance: -4.38%
Average Trading Volume: 387,602
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.93B
For a thorough assessment of XENE stock, go to TipRanks’ Stock Analysis page.
